Vericel Co. (NASDAQ:VCEL) Stock Holdings Raised by Congress Asset Management Co.

Congress Asset Management Co. raised its holdings in Vericel Co. (NASDAQ:VCEL - Free Report) by 37.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,291,720 shares of the biotechnology company's stock after buying an additional 351,550 shares during the quarter. Congress Asset Management Co. owned 2.66% of Vericel worth $54,575,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its holdings in Vericel by 65.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,430 shares of the biotechnology company's stock worth $398,000 after buying an additional 3,721 shares in the last quarter. PFG Investments LLC lifted its holdings in Vericel by 8.0% during the 3rd quarter. PFG Investments LLC now owns 7,400 shares of the biotechnology company's stock worth $313,000 after purchasing an additional 550 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 322 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 619 shares in the last quarter. Finally, OLD National Bancorp IN increased its stake in Vericel by 23.3% in the 3rd quarter. OLD National Bancorp IN now owns 5,513 shares of the biotechnology company's stock worth $233,000 after acquiring an additional 1,043 shares during the last quarter.

Insider Activity at Vericel

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the sale, the director now owns 11,000 shares of the company's stock, valued at $443,850. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at $443,850. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the company's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares of the company's stock, valued at $9,142,373.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,166 shares of company stock worth $1,200,764. Insiders own 5.20% of the company's stock.

Vericel Trading Down 3.3 %

VCEL traded down $1.50 during midday trading on Thursday, hitting $44.04. 254,450 shares of the company were exchanged, compared to its average volume of 427,160. Vericel Co. has a 1-year low of $32.28 and a 1-year high of $54.10. The company's 50 day simple moving average is $44.81 and its 200 day simple moving average is $46.35. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -4,404.00 and a beta of 1.67.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Vericel had a return on equity of 0.35% and a net margin of 0.37%. The company had revenue of $52.70 million for the quarter, compared to analysts' expectations of $52.59 million. During the same period in the previous year, the firm posted ($0.11) EPS. Vericel's revenue was up 14.8% compared to the same quarter last year. On average, equities analysts anticipate that Vericel Co. will post 0.12 EPS for the current year.

Analyst Upgrades and Downgrades

VCEL has been the topic of several recent research reports. BTIG Research reduced their price target on Vericel from $56.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, July 15th. Stephens lifted their target price on Vericel from $56.00 to $58.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. TD Cowen boosted their price objective on Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, August 27th. Truist Financial boosted their price objective on Vericel from $56.00 to $57.00 and gave the stock a "buy" rating in a research note on Tuesday, July 16th. Finally, HC Wainwright increased their price objective on Vericel from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $57.71.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.